Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study
Rattachement africain : dk, us, de, vn, gb. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Plain Language SummaryWhat is this summary about?Rimegepant is a new medicine that can be used to prevent migraine attacks or stop a migraine attack that has already started. Many people with migraine have tried a type of medicine called a ‘triptan’ to stop an attack that has already started. Some people find triptans to work well for the treatment of migraine. This summary describes findings from a study that looked to see if rimegepant could stop a migraine attack in people who have found triptans not to provide enough symptom relief, to cause bothersome side effects, or are not recommended to use triptans because of other conditions they have or medicines they take.What were the main results?People in this study took rimegepant or a placebo to treat a single migraine attack that caused them moderate or severe pain. People who took rimegepant had more relief from migraine pain and other symptoms than people who took the placebo. They were also more able to do their daily activities normally. Fewer people who took rimegepant needed to take additional medicines to treat their migraine pain and other symptoms than people who took the placebo. Similar proportions of people who took rimegepant or the placebo reported side effects.What do the results mean?Researchers found rimegepant can relieve the pain and other symptoms of a migraine attack in people who have found triptans not to provide enough symptom relief, to cause bothersome side effects, or are not recommended to use triptans.Clinical trial number: NCT05509400
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Can rimegepant stop symptoms of a migraine attack in people who have not found triptans to work well or are not recommended to use triptans? A plain language summary of a clinical study
- Date Crossref
- 03/04/2026
- Éditeur
- Informa UK Limited
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Rigshospitalet Danish Headache Center pays non établi dans la noticeÉtablissement de santé
-
New England Institute for Neurology and Headache pays non établi dans la noticeÉtablissement de santé
-
Cardiovascular Center Frankfurt pays non établi dans la noticeStructure de recherche
-
Vietnam National Children's Hospital pays non établi dans la noticeÉtablissement de santé
-
Pfizer (United Kingdom) pays non établi dans la noticeEntreprise
-
cHeadache Center Frankfurt pays non établi dans la noticeInstitution
-
dNational Institute of Neurology and Neurosurgery pays non établi dans la noticeStructure de recherche
-
ePfizer Inc pays non établi dans la noticeEntreprise
-
fPfizer Inc pays non établi dans la noticeEntreprise
-
gPfizer Inc pays non établi dans la noticeEntreprise
-
D UK Ltd hPfizer R& pays non établi dans la noticeEntreprise
Danish Headache Center — Rigshospitalet, New England Institute for Neurology and Headache et Cardiovascular Center Frankfurt, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.